AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30912296
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (GT) treatment for 4 months (after HW ingestion in Grp2)
Trial: 28712591
Drug: SPIOMET (spironolactone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPIOMET (spironolactone 50 mg/d, pioglitazone 7.5 mg/d, metformin 850 mg/d)
Trial: 25130321
Drug: Medications associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medications associated with weight gain
Trial: 23230066
Drug: 0 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg/kg/day iron supplementation (placebo)
Trial: 23230066
Drug: 1 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg/kg/day iron supplementation
Trial: 23230066
Drug: 2 mg/kg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg/day iron supplementation
Trial: 18837739
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (750 mg daily)
Trial: 16557483
Drug: SJW herb
RxNorm normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJW herb extract (LI‐160) 300 mg once daily
Trial: 16557483
Drug: SJW herb
RxNorm normalized name: Purslane Herb
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SJW herb extract (LI‐160) 300 mg twice daily
Trial: 14535628
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg/day) for 2 months
Trial: 10735496
Drug: Interferon-gamma (IFN-gamma)
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon-gamma (IFN-gamma) 0.1 mg subcutaneously on days 1, 3, 5, 15, 17, and 19 of each 28-day cycle along with 100 mg/m(2) cisplatin and 600 mg/m(2) cyclophosphamide
Trial: 10735496
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m(2) and cyclophosphamide 600 mg/m(2)
Trial: 8723395
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (class effect)
Trial: 8723395
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (various trials)
Trial: 1414156
Drug: Danazol 150
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Danazol 150 mg/day for patients under 15 years and 300 mg/day for older patients
Trial: 3908619
Drug: Polyadenylic-polyuridylic acid
RxNorm normalized name: polyacrylic acid (450000 MW)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyadenylic-polyuridylic acid (poly(A).poly(U)) as adjuvant treatment
Trial: 27832366
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein drink (PRO 23.9 ± 3.6 g protein)
Trial: 27832366
Drug: Dextrose drink
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose drink (CHO 26.5 ± 3.8 g carbohydrate)
Trial: 22289570
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein isolate (20 g)
Trial: 22289570
Drug: Micellar casein
RxNorm normalized name: Douxo Micellar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micellar casein (20 g)
Trial: 18049943
Drug: Soy phytoestrogens
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy phytoestrogens 55 mg
Trial: 16255136
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy for gastric cancer
Trial: 16255136
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy for gastric cancer
Trial: 12145148
Drug: Fish oils
RxNorm normalized name: fish oils
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oils (4 g/day)
Trial: 12145148
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment with atorvastatin and fish oils
Trial: 10103335
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of Ritalin
Trial: 10103335
Drug: 17.5 mg
RxNorm normalized name: acitretin 17.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.5 mg of Ritalin
Trial: 10103335
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg of Adderall
Trial: 10103335
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg of Adderall
Trial: 8852543
Drug: Lacidipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacidipine (4 mg once daily)
Trial: 6773725
Drug: High-dose insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose insulin (1.0 U/kg/h)
Trial: 6773725
Drug: Low-dose insulin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose insulin (0.1 U/kg/h)
Trial: 31696371
Drug: Daily-use product
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily-use product
Trial: 28094033
Drug: saline+10μg/ml‐1 vancomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline+10μg/ml‐1 vancomycin (vanco group)
Trial: 15383107
Drug: Diclofenac suppositories
RxNorm normalized name: diclofenac Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac suppositories (two x 100 mg)
Trial: 15383107
Drug: Placebo suppositories
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suppositories (Anusol)
Trial: 11195739
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cefepime
Trial: 11195739
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g cefepime
Trial: 9703380
Drug: GHRH infusion
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH infusion (0.33 microg/kg every 90 min for 3 days)
Trial: 2897978
Drug: Suriclone 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suriclone 0.4 mg
Trial: 7927120
Drug: Suriclone 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suriclone 0.4 mg + Imipramine 75 mg
Trial: 2789922
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 25 mg folinic acid
Trial: 2789922
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 25 mg folinic acid
Trial: 788759
Drug: Hydrallazine (75‐150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrallazine (75‐150 mg/day)
Trial: 788759
Drug: Phentolamine (60‐120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine (60‐120 mg/day)
Trial: 29351538
Drug: Cotrimoxazole 960
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole 960 mg tablets p.o. administered 14 and 2 hours before catheter removal
Trial: 29351538
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics administered
Trial: 19951427
Drug: Dimeticone 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimeticone 4% lotion
Trial: 7506145
Drug: Naproxen (500mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (500mg twice daily)
Trial: 27565018
Drug: Dual antithrombotic
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antithrombotic therapy with dabigatran etexilate (110 or 150 mg twice daily) and a P2Y12 inhibitor (either clopidogrel or ticagrelor)
Trial: 27565018
Drug: Triple antithrombotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antithrombotic therapy with warfarin, a P2Y12 inhibitor (either clopidogrel or ticagrelor), and low-dose aspirin (for 1 or 3 months, depending on stent type)
Trial: 25000528
Drug: Palmitate treatment
RxNorm normalized name: palmitate
DrugBank: Palmitic Acid (DB03796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitate treatment (300 µM) for three days
Trial: 25000528
Drug: Palmitate treatment
RxNorm normalized name: palmitate
DrugBank: Palmitic Acid (DB03796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palmitate treatment (300 µM) for one day
Trial: 10809860
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied NG-monomethyl-L-arginine (L-NMMA) in aqueous cream BP
Trial: 10809860
Drug: Aqueous cream
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous cream BP alone (control)
Trial: 8752293
Drug: Quadrivalent rhesus
RxNorm normalized name: Fluarix Quadrivalent 2018-2019
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quadrivalent rhesus rotavirus-based human rotavirus vaccine
Trial: 29565762
Drug: Ergocalciferol 50,000
RxNorm normalized name: ergocalciferol 50,000 intl units oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ergocalciferol 50,000 IU (treatment)
Trial: 29565762
Drug: Crossover from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover from control to treatment group (for months 6-10)
Trial: 26462724
Drug: G-CSF (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (6 mg administered subcutaneously every 2 weeks for 12 weeks)
Trial: 22587573
Drug: Topical ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical ketorolac 0.5% drops
Trial: 19799615
Drug: Nicotine Replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Replacement Therapy (NRT) for 29 days
Trial: 17566099
Drug: l-arginine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine with ghrelin
Trial: 17566099
Drug: l-arginine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine with CRH
Trial: 17566099
Drug: ghrelin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ghrelin and CRH with l-arginine
Trial: 11257751
Drug: Local corticosteroid
RxNorm normalized name: Corticosteroids acting locally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local corticosteroid injections
Trial: 6152880
Drug: Beta-receptor blockade
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-receptor blockade continued until surgery (n = 48)
Trial: 6152880
Drug: Beta-receptor blockade
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-receptor blockade gradually withdrawn (n = 51)
Trial: 30835307
Drug: Placebo without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo without therapy (n=257)
Trial: 30835307
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with therapy (n=256)
Trial: 30835307
Drug: Supplements without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supplements without therapy (n=256)
Trial: 30835307
Drug: Supplements with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplements with therapy (n=256)
Trial: 29039320
Drug: Ketoprofen 100
RxNorm normalized name: ketoprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoprofen 100 mg fast dispersible tablets (test)
Trial: 21561896
Drug: GLP‐1 infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP‐1 infusion at 1.2 pmol/kg/min starting 30 min before dobutamine stress echocardiography (DSE)
Trial: 21561896
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no GLP‐1 infusion)
Trial: 17475965
Drug: (18)F‐FDG PET/CT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (18)F‐FDG PET/CT with delayed images after furosemide and oral hydration
Trial: 25992523
Drug: Bromazepam (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam (6 mg)
Trial: 1579628
Drug: Bromazepam (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam (12 mg)
Trial: 1579628
Drug: Bromazepam (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam (6 mg and 12 mg)
Trial: 4040550
Drug: High-dose cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cisplatin (120 mg/m2)
Trial: 4040550
Drug: Low-dose cisplatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cisplatin (60 mg/m2)
Trial: 31319633
Drug: MCT in
RxNorm normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT in liquid form (MCT-L)
Trial: 31319633
Drug: LCT in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCT in liquid form (Con-L)
Trial: 11826229
Drug: Xylitol lozenges
RxNorm normalized name: xylitol Oral Lozenge
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xylitol lozenges
Trial: 15932659
Drug: Spironolactone 40
RxNorm normalized name: spironolactone 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 40 mg/d
Trial: 12460700
Drug: CC genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC genotype in white participants with treated hypertension
Trial: 12460700
Drug: CC genotype
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC genotype in white participants
Trial: 10342710
Drug: DHEA 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA 200 mg/d
Trial: 29926711
Drug: 20 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 μg HBV vaccine
Trial: 29926711
Drug: 40 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 μg HBV vaccine
Trial: 26542491
Drug: liraglutide (1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liraglutide (1.8 mg before intervention, followed by 0.6 mg for 2 days, 1.2 mg for 2 days, and 1.8 mg for 3 days)
Trial: 17690713
Drug: Advances in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advances in antigen-specific therapies
Trial: 8519716
Drug: Intravenous ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketorolac (group 2)
Trial: 2191712
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (400 mg)
Trial: 2191712
Drug: Acyclovir ophthalmic
RxNorm normalized name: acyclovir Ophthalmic Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir ophthalmic ointment (3%)
Trial: 31775064
Drug: Daily assessment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily assessment schedule
Trial: 31775064
Drug: Weekly assessment
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly assessment schedule
Trial: 31420412
Drug: Primary cytoreductive
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary cytoreductive surgery followed by 6 cycles of platinum-based chemotherapy
Trial: 31420412
Drug: Interval cytoreductive
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interval cytoreductive surgery following 3 cycles of neoadjuvant chemotherapy and then 3 cycles of platinum-based chemotherapy
Trial: 23334782
Drug: Pregabalin 150
RxNorm normalized name: pregabalin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin 150 mg po one hour before surgery
Trial: 16508700
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg calcium plus 800 IU cholecalciferol (n=33)
Trial: 16508700
Drug: 1,200 mg
RxNorm normalized name: lecithin 1,200 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 mg calcium (n=31)
Trial: 11775134
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg eprosartan
Trial: 11775134
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg eprosartan
Trial: 8276044
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) at 0.02 microgram.kg‐1.min‐1 infusion during bypass
Trial: 11876707
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg/day) and lansoprazole (30 mg/day)
Trial: 11876707
Drug: Moxifloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin (400 mg/day), lansoprazole (30 mg/day), and clarithromycin (500 mg b.d.)
Trial: 29306453
Drug: Caffeine containing
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine containing weight loss supplement
Trial: 27389521
Drug: Nine further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine further sessions of integrated treatment
Trial: 27389521
Drug: Nine further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine further sessions of alcohol-focused treatment
Trial: 27389521
Drug: Nine further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine further sessions of depression-focused treatment
Trial: 27389521
Drug: Integrated interventions
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Integrated interventions (incorporating motivational interviewing and cognitive behaviour therapy)
Trial: 22795645
Drug: Oxytocin administration
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxytocin administration to father
Trial: 22795645
Drug: Placebo administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration to father
Trial: 20082715
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of melatonin and omeprazole
Trial: 12207630
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (200 ml)
Trial: 12207630
Drug: Tap water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tap water (200 ml)
Trial: 10792845
Drug: G-CSF (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (0.3 mg/ml, 3 times a week for 12 weeks)
Trial: 8777829
Drug: CO2-enriched (5%)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2-enriched (5%) gas mixture with low-dose scopolamine (scopoderm TTS)
Trial: 8777829
Drug: Voluntary hyperventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voluntary hyperventilation with low-dose scopolamine (scopoderm TTS)
Trial: 6097665
Drug: Enalapril maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril maleate (40 mg) in fasting state
Trial: 6097665
Drug: Enalapril maleate
RxNorm normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Enalapril maleate (40 mg) with a standard breakfast
Trial: 20932583
Drug: Baerveldt glaucoma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baerveldt glaucoma implant (BGI)
Trial: 29908803
Drug: Fixed milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed milk allowance (FIX) of 6 to 8 L/d from day 1 after birth
Trial: 29908803
Drug: Slowly increasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slowly increasing milk allowance (INC) starting from 4 to 5 L/d to reach 6 to 8 L/d over 7 to 14 days
Trial: 22652379
Drug: Tomato paste
RxNorm normalized name: Tomato
DrugBank: Tomato (DB10573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato paste supplementation (70 g containing 33.3 mg of lycopene)
Trial: 16115357
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg elemental Cu/d as CuSO4
Trial: 16115357
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg elemental Cu/d as CuSO4
Trial: 16115357
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg elemental Cu/d (control)
Trial: 1722167
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 alpha-reductase inhibitor); varying doses administered to men with benign prostatic hyperplasia.
Trial: 28925286
Drug: High dosage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dosage VFE (four times)
Trial: 28925286
Drug: Traditional dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional dosage VFE (twice)
Trial: 28925286
Drug: Low dosage
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dosage VFE (once)